$40 – $55

Teaching Old Drugs New Tricks: The Promise and Pitfalls of Drug Repurposing

Event Information

Share this event

Date and Time

Location

Location

FOLEY HOAG LLP

Seaport West

155 Seaport Boulevard

Boston, MA 02210

View Map

Refund Policy

Refund Policy

Refunds up to 1 day before event

Event description

Description


The application of existing therapeutics to new disease indications holds enormous promise. Repurposed (sometimes call repositioned) drugs can be brought to market and have clinical impact faster and at much lower cost than de novo drug discovery. Commercializing an existing drug nevertheless presents challenges, even more so when the drug is a biologic. These span patent protection, regulatory and reimbursement treatment, off label competition from the existing generic, venture capital willingness to fund, and of course exit valuation.

Keynote Speaker

Steven Corsello, MD, Postdoctoral Fellow, Broad Institute

Dr. Corsello is the founder of the Drug Repurposing Hub at the Broad Institute and an attending physician at the Dana-Farber Cancer Institute. He currently leads an effort to evaluate all available clinical drugs using information-rich cellular assays to develop new cancer treatments.

Moderator

Jules Fried, CEO, Vasogenesis LLC

Jules is a serial entrepreneur, co-founder, and Chief Executive Officer of Vasogenesis LLC, a clinical stage drug company repurposing an off-patent biologic to treat vascular disease.

Panelists

John Edwards, CEO and Founder, Drusolv Therapeutics Inc.

Drusolv Therapeutics, a clinical stage drug company that is repurposing statins for early intervention in age-related macular degeneration, in partnership with Massachusetts Eye and Ear.

Alexander “Zan” Fleming, MD, Founder and Executive Chairman, Kinexum LLC

Kinexum is a translational research consulting firm founded to support, accelerate, and advance efficient healthcare product innovation.

Janine Ladislaw, PhD, Registered Patent Attorney, Foley Hoag LLP

Janine’s practice focuses on strategic IP counseling, including patent procurement and monetization for emerging companies, public corporations, universities, and independent research institutions.

Alex Zisson, Managing Director, HIG Biotech Partners

At HIG, Alex focuses on investments in the biopharmaceuticals industry especially in pharmaceuticals, generics, drug delivery, and specialty pharma and biotechnology.

Join this timely program to hear about a unique drug development resource created by the Broad Institute and panelists experienced with the issues involved with bringing an off patent drug to market for a new use.

What to Expect

Our keynote speaker will describe the development and experience of the Drug Repurposing Hub while panelists comment upon the following topics associated with repurposing:

  • Expenses avoided by repurposing
  • Patent considerations
  • Attitude of investors and strategic partners
  • Regulatory pathways

Who should attend

C-level executives, board members, healthcare providers, venture capital and private equity investors, and anyone who wants a better understanding of opportunities and pitfalls of repurposing off patent drugs.


Speaker Bios

Steven Corsello, MD, Postdoctoral Fellow, Broad Institute

Dr. Steven Corsello is the founder of the Drug Repurposing Hub at the Broad Institute, an effort to evaluate all available clinical drugs using information-rich cellular assays to develop new cancer treatments. Their library now contains over 6,000 unique compounds that have been assayed for purity and annotated for structure, clinical development status, mechanism of action, approved indications, and more. The Drug Repurposing Hub is a close collaboration between the Broad Institute Cancer Program, the Center for the Development of Therapeutics, and the Connectivity Map group. As a member of Todd Golub’s laboratory, Dr. Corsello applies new cellular technologies to cancer therapeutic discovery. As a key contributor to the Connectivity Map project, he also develops translational applications for perturbational gene expression profiling.

Dr. Corsello is also an attending physician at the Dana-Farber Cancer Institute. Post-doctoral scholar at Broad Institute since 2013. Before that, he was a Hematology/Oncology Fellow and then Instructor in Medicine at Dana Farber Cancer Institute. He completed residency training in internal medicine at Massachusetts General Hospital and a combined fellowship program in hematology and medical oncology at the Dana-Farber Cancer Institute. Dr. Corsello holds an A.B. in biochemical sciences from Harvard College and an M.D. from Harvard Medical School, where he developed gene expression-based screening approaches for leukemia.

John Edwards, CEO and Founder, Drusolv Therapeutics, Inc.

John Edwards is a successful serial entrepreneur with 25 years of experience in medical product development and commercialization. He is founder and CEO of Drusolv Therapeutics, a clinical-stage drug company that is repurposing statins for early intervention in age-related macular degeneration (AMD), a blinding eye disease, in partnership with Massachusetts Eye and Ear. John also co-founded MacuLogix, a company successfully commercializing a diagnostic for early detection of AMD. In addition to Drusolv and MacuLogix, his experience as an entrepreneur includes one company that was acquired and one that went public. Mr. Edwards has BS and MS degrees in physics from MIT and an MBA from University of Chicago.

Alexander “Zan” Fleming, MD, Founder and Executive Chairman, Kinexum LLC

Dr. Alexander Fleming is Founder and Executive Chairman of Kinexum, a full service translational research consulting firm founded a decade ago to support, accelerate, and advance efficient healthcare product innovation. They possess multidisciplinary expertise regarding various metabolic diseases including diabetes, obesity, metabolic syndrome, cardiometabolic, inflammation, immune modulation, oncology, retinopathy, neuropathy, and more. Offerings include regulatory strategy and services, nonclinical services, CMC services, clinical trial management, medical writing and document management, clinical development and medical monitoring, quality assurance, and quality control.

At the US Food and Drug Administration from 1986-98, Dr. Fleming was responsible for the therapeutic areas of diabetes, other metabolic and endocrine disorders, growth and development, nutrition, lipid-lowering compounds, and reproductive indications. He led reviews of landmark approvals, including metformin and the first statin, insulin analog, PPAR-agonist, and growth hormone for non-GH deficiency indications. Dr. Fleming oversaw clinical review of the earliest biotech products, including human insulin and growth hormone. He also helped shape FDA policies and practices related to therapeutic review and regulatory communication. He was a major contributor to FDA's Good Review Practice (GRP) initiative and led the committee responsible for education and training at CDER. He conceived and directed the first FDA pilot project to utilize the internet for regulatory communication.

Dr. Fleming also serves as President and Chief Executive Officer of Tolerion, https://tolerion.bio, a biotechnology company developing disease-modifying treatments for type 1 diabetes and other autoimmune diseases.

He completed fellowship training in endocrinology at Vanderbilt and metabolism at National Institutes of Health, where he was a senior fellow. Dr. Fleming received his M.D. and internal medicine training from Emory University.

Jules Fried, CEO, Vasogenesis LLC

Jules Fried is a serial entrepreneur, co-founder, and Chief Executive Officer of Vasogenesis LLC, a clinical stage drug company repurposing an off patent biologic to treat vascular disease without surgical intervention. Before Vasogenesis, Jules was CEO of Interactive Motion Technologies, a manufacturer of robotic rehabilitation equipment for stroke victims which he sold to a microcap public company. He was also a Principal at Atlantic VIC, a technology venture development company licensing technology out of local research institutions, and founder and board member of First Commons Bank, one of the fastest growing community banks in the country, sold last year to Brookline Bank. Earlier in his career, he built and led a two-time Inc. 500 digital printing peripheral equipment manufacturer as a member of the founding management team. Before that, Jules was a partner in the law firm of McDermott, Will & Emery, having co-founded a boutique health care law firm that became their Boston office. Mr. Fried started his legal career in the Antitrust Division of the US Department of Justice and was part of the team responsible for the litigation resulting in the breakup of AT&T. He has a J.D cum laude from the University of Michigan Law School, and is an A.B. from Princeton University. Jules has led many successful NEHEN programs.

Janine Ladislaw, PhD, Registered Patent Attorney, Foley Hoag LLP

Dr. Janine Ladislaw is a Registered Patent Attorney in the Boston office of Foley Hoag, one of Boston’s premier life science law firms. Her practice focuses on strategic intellectual property counseling, including patent procurement and monetization for emerging companies, public corporations, universities, and independent research institutions. Janine brings over a decade of law firm experience to her IP practice, during which she has counseled clients in a wide range of technical areas, such as pharmaceuticals, drug delivery, small molecule drug discovery, and synthetic methods. Prior to joining the firm, she obtained her Ph.D. in organic chemistry from the University of Pennsylvania

Alex Zisson, Managing Director, HIG Biotech Partners

Alex Zisson has over twenty-five years of experience analyzing and investing in biotech, pharma, drug delivery and diagnostics. He joined HIG BioHealth Partners as a Managing Director in January 2016 and focuses on investments in the biopharmaceuticals industry, especially in pharmaceuticals, generics, drug delivery and specialty pharma and biotechnology. He serves on the boards of directors for Arvelle Therapeutics, Clarus Therapeutics, Leiter’s Pharmacy, Neurana Pharmaceuticals, and Taconic Biosciences.

Before H.I.G., Alex spent 13 years making similar investments at Thomas, McNerney & Partners. Before that, he spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan) where Alex led research teams covering the biotechnology, specialty pharmaceuticals, large-cap pharmaceuticals, drug delivery and diagnostics industries. Alex became the firm’s healthcare strategist after the merger of Chase H&Q and JPMorgan. He was twice named in The Wall Street Journal All-Star Analysts Survey, including his last year at JPMorgan when he was ranked #1 in pharmaceuticals stock picking, tied for #2 in earnings estimate accuracy, and #8 across all industries in ‘home run’ hitting.

Alex is co-chair of the Industry Advisory Board of the Children’s Tumor Foundation, an advisor for the Partnership Fund of NYC which manages a bioaccelarator to advance local healthcare research, and is on the Life Sciences Council for Springboard Enterprises, a group that assists women entrepreneurs. He is also a board member for the Greenwich Council of the Boy Scouts of America. He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.



SPONSORSHIP KINDLY PROVIDED BY:

Alira Health







Swifton CFOs

Share with friends

Date and Time

Location

FOLEY HOAG LLP

Seaport West

155 Seaport Boulevard

Boston, MA 02210

View Map

Refund Policy

Refunds up to 1 day before event

Save This Event

Event Saved